We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

By LabMedica International staff writers
Posted on 06 Jun 2025

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess immune protection. More...

Conventional methods require large blood samples and lengthy processing times. Now, researchers have developed a compact diagnostic platform, known as the Tip Optofluidic Immunoassay (TOI), that can evaluate antibody protection using just a single microliter of fingertip blood, delivering results in only 40 minutes.

The TOI platform was developed by scientists at Shenzhen Institutes of Advanced Technology (SIAT, Guangdong, China) and the Chinese Academy of Sciences (CAS, Beijing, China), in collaboration with multiple research partners. The initiative brings together expertise in biosensing, microfluidics, and synthetic biology to meet the growing need for accessible, field-ready diagnostic solutions. TOI works by integrating microfluidic biosensing with chemiluminescence detection in a portable format. At its core are high-affinity polystyrene immuno-reactors, which interface directly with standard pipette tips. These reactors are used in tandem with a portable chemiluminescent imaging station, enabling rapid and quantitative measurement of IgG binding levels, binding kinetics, and virus inhibition—all from a tiny drop of fingertip blood. The system operates without the need for complex lab equipment or high sample volumes.

Compared to standard assays like ELISA or virus neutralization tests (VNTs), TOI significantly reduces both processing time and operational complexity. It delivers detection sensitivity at around 0.1 ng/mL, spans a dynamic range of 3 to 4.5 orders of magnitude, and achieves a signal-to-noise ratio of over 10,000. One of the platform’s key innovations is RIVIA 2.0, a rapid in vitro inhibition assay designed to simulate viral neutralization. Using rationally engineered SARS-CoV-2 spike ectodomain (S-ECD) trimers tagged with orientation-specific Avi-biotin, the system achieves precise and reproducible antibody activity measurements in just 20 minutes. The system was validated using 135 blood samples from 113 individuals, with a subset monitored over six months. TOI successfully identified broad-spectrum, high-titer antibody responses, especially in individuals with hybrid vaccine regimens.

Researchers also proposed a preliminary IgG concentration threshold of ~20 ng/mL, potentially linked to reduced short-term infection risk, indicating the test’s potential for predictive immune monitoring. Beyond COVID-19, the platform’s low sample requirement and portability make it suitable for other infectious diseases such as influenza and hepatitis, and for deployment in remote or resource-limited settings. TOI also offers valuable applications in therapeutic antibody development and vaccine efficacy studies, making it a versatile tool for both clinical and research use. This study demonstrates how TOI bridges the gap between advanced laboratory diagnostics and real-world application. By combining speed, sensitivity, and multi-dimensional immune assessment in a highly compact format, TOI sets a new benchmark for personalized and scalable infectious disease management.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.